{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:01:24Z","timestamp":1783443684854,"version":"3.54.6"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Children with skeletal dysplasia are frequently referred to pediatric endocrinologists due to short stature. These children may present with disproportionate growth or medical histories that point to a skeletal dysplasia. This primer will discuss when to be concerned about skeletal dysplasia, the initial steps in evaluation for a skeletal dysplasia, and new therapies that are either recently approved or in development.<\/jats:p>","DOI":"10.3389\/fped.2023.1229666","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:19:38Z","timestamp":1692699578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["What the pediatric endocrinologist needs to know about skeletal dysplasia, a primer"],"prefix":"10.3389","volume":"11","author":[{"given":"Janet M.","family":"Legare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Basel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","article-title":"Nosology of genetic skeletal disorders: 2023 revision","author":"Unger","year":"2023","journal-title":"Am J Med Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/DDDT.S219433","article-title":"Clinical utility of elosulfase alfa in the treatment of morquio a syndrome","volume":"16","author":"Lee","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12018-020-09272-5","article-title":"Current and emerging therapies for pediatric bone diseases","volume":"18","author":"Ukarapong","year":"2020","journal-title":"Clin Rev Bone Miner Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/mop.0000000000000914","article-title":"Diagnosis and management of pediatric metabolic bone diseases associated with skeletal fragility","volume":"32","author":"Charoenngam","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bone.2017.03.045","article-title":"Novel therapeutic interventions for pseudoachondroplasia","volume":"102","author":"Posey","year":"2017","journal-title":"Bone"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1111\/bcp.15369","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP","volume":"88","author":"Breinholt","year":"2022","journal-title":"Br J Clinic Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jbm4.10190","article-title":"FGF23, hypophosphatemia, and emerging treatments","volume":"3","author":"Imel","year":"2019","journal-title":"JBMR Plus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"387","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-019-1222-2","article-title":"The evolving therapeutic landscape of genetic skeletal disorders","volume":"14","author":"Sabir","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2042018820904016","article-title":"New perspectives on the treatment of skeletal dysplasia","volume":"11","author":"Marzin","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.yapd.2022.03.005","article-title":"Clinical indications for growth hormone therapy","volume":"69","author":"Danowitz","year":"2022","journal-title":"Adv Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000074504","article-title":"Skeletal dysplasia, growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short children","volume":"60","author":"Hagenas","year":"2003","journal-title":"Horm Res"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199935710.001.0001","volume-title":"Handbook of physical measurements","author":"Gripp","year":"2013"},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jpeds.2020.06.051","article-title":"Sitting height to standing height ratio reference charts for children in the United States","volume":"226","author":"Hawkes","year":"2020","journal-title":"J Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/ijerph7031047","article-title":"Leg length, body proportion, and health: a review with a note on beauty","volume":"7","author":"Bogin","year":"2010","journal-title":"Int J Environ Res Public Health"},{"key":"B19","article-title":"Type II collagen disorders overview","volume-title":"Genereviews\u00ae","author":"Gregersen","year":"1993"},{"key":"B20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ajmg.c.31335","article-title":"TRPV4-associated skeletal dysplasias","volume":"160","author":"Nishimura","year":"2012","journal-title":"Am J Med Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/dvdy.221","article-title":"Multiple epiphyseal dysplasia and related disorders: molecular genetics, disease mechanisms, and therapeutic avenues","volume":"250","author":"Dennis","year":"2021","journal-title":"Dev Dyn"},{"key":"B22","article-title":"Achondroplasia","volume-title":"Genereviews\u00ae","author":"Legare","year":"1998"},{"key":"B23","article-title":"Pseudoachondroplasia","volume-title":"Genereviews\u00ae","author":"Briggs","year":"2004"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000444596","article-title":"SHOX haploinsufficiency as a cause of syndromic and nonsyndromic short stature","volume":"7","author":"Fukami","year":"2016","journal-title":"Mol Syndromol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/TACG.S197205","article-title":"COL2A1 gene mutations: mechanisms of spondyloepiphyseal dysplasia congenita","volume":"12","author":"Nenna","year":"2019","journal-title":"Appl Clin Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/cge.13680","article-title":"Integrated analysis of COL2A1 variant data and classification of type II collagenopathies","volume":"97","author":"Zhang","year":"2020","journal-title":"Clin Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000495778","article-title":"Combined phenotypes of spondylometaphyseal dysplasia-kozlowski type and charcot-marie-tooth disease type 2C secondary to a TRPV4 pathogenic variant","volume":"10","author":"Faye","year":"2019","journal-title":"Mol Syndromol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1007\/s12325-019-01174-3","article-title":"Paediatric metabolic bone disease: a lifetime ahead","volume":"37","author":"Gomez-Alonso","year":"2020","journal-title":"Adv Therapeutics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11926-018-0778-5","article-title":"Hypophosphatasia: from diagnosis to treatment","volume":"20","author":"Simon","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/phar.2017.00079","article-title":"Skeletal dysplasias: growing therapy for growing bones","volume":"8","author":"Jelin","year":"2017","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/jbmr.4410","article-title":"The diverse origin of bone-forming osteoblasts","volume":"36","author":"Mizoguchi","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","article-title":"Achondroplasia: development, pathogenesis, and therapy","volume":"246","author":"Ornitz","year":"2017","journal-title":"Dev Dyn"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1371\/journal.pone.0081569","article-title":"Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1210\/en.2014-1914","article-title":"Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene","volume":"156","author":"Matsushita","year":"2015","journal-title":"Endocrinology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229639","article-title":"Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia","volume":"15","author":"Kitoh","year":"2020","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/etm.2022.11738","article-title":"Meclozine ameliorates bone mineralization and growth plate structure in a mouse model of X-linked hypophosphatemia","volume":"25","author":"Kamiya","year":"2023","journal-title":"Exp Ther Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"CD005088","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dawn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/jbmr.4382","article-title":"Gene therapy using adeno-associated virus serotype 8 encoding TNAP-d10 improves the skeletal and dentoalveolar phenotypes in ALPL -\/- mice","volume":"36","author":"Kinoshita","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5114\/pedm.2019.89642","article-title":"Recombinant parathyroid hormone for hypoparathyroidism in children: a narrative review","volume":"25","author":"Dayal","year":"2019","journal-title":"Pediatr Endocrinol Diabetes Metab"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1229666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:19:42Z","timestamp":1692699582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1229666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":41,"alternative-id":["10.3389\/fped.2023.1229666"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1229666","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"article-number":"1229666"}}